Detailed Information
Cited 4 time in 
Cited 3 time in 
Cited 3 time in
Metadata Downloads
Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine
- Authors
- Park, J.[Park, J.]; Le, A.K.[Le, A.K.]; Tseng, T.-C.[Tseng, T.-C.]; Yeh, M.-L.[Yeh, M.-L.]; Jun, D.W.[Jun, D.W.]; Trinh, H.[Trinh, H.]; Wong, G.L.H.[Wong, G.L.H.]; Chen, C.-H.[Chen, C.-H.]; Peng, C.-Y.[Peng, C.-Y.]; Kim, S.E.[Kim, S.E.]; Oh, H.[Oh, H.]; Kwak, M.-S.[Kwak, M.-S.]; Cheung, K.S.[Cheung, K.S.]; Toyoda, H.[Toyoda, H.]; Hsu, Y.-C.[Hsu, Y.-C.]; Jeong, J.Y.[Jeong, J.Y.]; Yoon, E.L.[Yoon, E.L.]; Ungtrakul, T.[Ungtrakul, T.]; Zhang, J.[Zhang, J.]; Xie, Q.[Xie, Q.]; Ahn, S.B.[Ahn, S.B.]; Enomoto, M.[Enomoto, M.]; Shim, J.-J.[Shim, J.-J.]; Cunningham, C.[Cunningham, C.]; Jeong, S.W.[Jeong, S.W.]; Cho, Y.K.[Cho, Y.K.]; Ogawa, E.[Ogawa, E.]; Huang, R.[Huang, R.]; Lee, D.-H.[Lee, D.-H.]; Takahashi, H.[Takahashi, H.]; Tsai, P.-C.[Tsai, P.-C.]; Huang, C.-F.[Huang, C.-F.]; Dai, C.-Y.[Dai, C.-Y.]; Tseng, C.-H.[Tseng, C.-H.]; Yasuda, S.[Yasuda, S.]; Kozuka, R.[Kozuka, R.]; Li, J.[Li, J.]; Wong, C.[Wong, C.]; Wong, C.C.[Wong, C.C.]; Zhao, C.[Zhao, C.]; Hoang, J.[Hoang, J.]; Eguchi, Y.[Eguchi, Y.]; Wu, C.[Wu, C.]; Tanaka, Y.[Tanaka, Y.]; Gane, E.[Gane, E.]; Tanwandee, T.[Tanwandee, T.]; Cheung, R.[Cheung, R.]; Yuen, M.-F.[Yuen, M.-F.]; Lee, H.-S.[Lee, H.-S.]; Yu, M.-L.[Yu, M.-L.]; Kao, J.-H.[Kao, J.-H.]; Yang, H.-I.[Yang, H.-I.]; Nguyen, M.H.[Nguyen, M.H.]
- Issue Date
- Apr-2022
- Publisher
- W.B. Saunders
- Keywords
- Antiviral Therapy; Epidemiology; Inactive Patients; Natural History; Untreated patients
- Citation
- Clinical Gastroenterology and Hepatology, v.20, no.4, pp.874 - 885.e4
- Indexed
- SCIE
SCOPUS
- Journal Title
- Clinical Gastroenterology and Hepatology
- Volume
- 20
- Number
- 4
- Start Page
- 874
- End Page
- 885.e4
- ISSN
- 1542-3565
- Abstract
- Background & AIMS: Antiviral treatment criteria are based on disease progression risk, and hepatocellular carcinoma (HCC) surveillance recommendations for patients with chronic hepatitis B (CHB) without cirrhosis is based on an annual incidence threshold of 0.2%. However, accurate and precise disease progression estimate data are limited. Thus, we aimed to determine rates of cirrhosis and HCC development stratified by age, sex, treatment status, and disease activity based on the 2018 American Association for the Study of Liver Diseases and 2017 European Association for the Study of the Liver guidelines. Methods: We analyzed 18,338 patients (8914 treated, 9424 untreated) from 6 centers from the United States and 27 centers from Asia-Pacific countries. The Kaplan-Meier method was used to estimate annual progression rates to cirrhosis or HCC in person-years. Results: The cohort was 63% male, with a mean age of 46.19 years, with baseline cirrhosis of 14.3% and median follow up of 9.60 years. By American Association for the Study of Liver Diseases criteria, depending on age, sex, and disease activity, annual incidence rates ranged from 0.07% to 3.94% for cirrhosis, from 0.04% to 2.19% for HCC in patients without cirrhosis, and from 0.40% to 8.83% for HCC in patients with cirrhosis. Several subgroups of patients without cirrhosis including males younger than 40 years of age and females younger than 50 years of age had annual HCC risk near or exceeding 0.2%. Similar results were found using European Association for the Study of the Liver criteria. Conclusion: There is great variability in CHB disease progression rates even among “lower-risk” populations. Future CHB modeling studies, public health planning, and HCC surveillance recommendation should be based on more precise disease progression rates based on sex, age, and disease activity, plus treatment status. © 2021 AGA Institute
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.